Venoruton® vs Daflon®: Evaluation of effects on quality of life in chronic venous insufficiency

Angiology

Volumn 57, Issue 2, 2006, Pages 131-138

  Cesarone, M R ^a   Belcaro, G ^a,b   Pellegrini, L ^a   Ledda, A ^a   Vinciguerra, G ^a   Ricci, A ^a   Di Renzo, A ^a   Ruffini, I ^a   Gizzi, G ^a   Ippolito, E ^a   Fano, F ^a   Dugall, M ^a   Acerbi, G ^a   Cornelli, U ^a   Hosoi, M ^a   Cacchio, M ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b PAP/PEA Project   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DAFLON; MONOXERUTIN; ANTICOAGULANT AGENT; DIOSMIN; DRUG DERIVATIVE; TROXERUTIN;

ADULT; AGE DISTRIBUTION; AGED; ANKLE EDEMA; ARTICLE; CHRONIC VEIN INSUFFICIENCY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISEASE SEVERITY; DRUG EFFICACY; EXERCISE; GENERAL PRACTITIONER; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MEDICAL SPECIALIST; MICROANGIOPATHY; PAIN; PRURITUS; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RECREATION; REGISTER; SCLEROTHERAPY; SELF CONCEPT; SEX RATIO; SOCIAL INTERACTION; STATISTICAL ANALYSIS; TABLET; VEIN SURGERY; WALKING; BLOOD FLOW VELOCITY; CHRONIC DISEASE; COLOR ULTRASOUND FLOWMETRY; DRUG EFFECT; FEMALE; FOLLOW UP; MALE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; POPLITEAL VEIN; PROSPECTIVE STUDY; PSYCHOLOGICAL ASPECT; TREATMENT OUTCOME; VEIN INSUFFICIENCY;

ADMINISTRATION, ORAL; ADULT; AGED; ANTICOAGULANTS; BLOOD FLOW VELOCITY; CHRONIC DISEASE; DIOSMIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYETHYLRUTOSIDE; MALE; MIDDLE AGED; POPLITEAL VEIN; PROSPECTIVE STUDIES; QUALITY OF LIFE; TREATMENT OUTCOME; ULTRASONOGRAPHY, DOPPLER, COLOR; VENOUS INSUFFICIENCY;

EID: 33645740058     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/000331970605700201     Document Type: Article

References (33)

1. 2 measurements, leg volumetry and ambulatory venous pressure measurements. Phlebology 4:23-26, 1989.
2. Cesarone MR, Ricci A, Belcaro G, et al: Acute effect of hydroxyethylrutosides on capillary filtration in normal volunteers, patients with venous hypertension and in patients with diabetic microangiopathy (a dose-comparison study). Vasa 21:76-79, 1992.
3. Belcaro G, Errichi BM: Evaluation of capillary permeability in patients with venous hypertension treated with Venoruton by the vacuum suction chamber (VSC) device. Phlebologie 41:847-849, 1988.
4. Incandela L, Belcaro G, Renton S, et al: HR(Paroven, Venoruton; 0(beta-hydroxyethyl)-rutosides) in venous hypertensive microangiopathy: A prospective, placebo-controlled, randomized trial. J Cardiovasc Pharmacol Ther 7(suppl I):S7-S10, 2002.
5. Incandela L, Cesarone MR, Belcaro G, et al: Treatment of diabetic microangiopathy and edema with HR(Paroven, Venoruton; 0(beta-hydroxyethyl)- rutosides): A prospective, placebo-controlled, randomized study. J Cardiovasc Pharmacol Ther 7(suppl I): S11-S13, 2002.
6. Cesarone MR, Incandela L, De Sanctis MT, et al: Treatment of edema and increased capillary filtration in venous hypertension with HR(Paroven, Venoruton; 0(beta-hydroxyethyl)-rutosides): A clinical, prospective, placebo-controlled, randomized, dose-ranging trial. J Cardiovasc Pharmacol Ther 7(suppl I):S21-S25, 2002.
7. Poynard T, Valterio C: Meta-analysis of hydroxyethylrutosides in the treatment of chronic venous insufficiency. Vasa 23:244-260, 1994.
8. De Sanctis MT, Cesarone MR, Incandela L, et al: Methods of evaluation and quantification of microangiopathy in high perfusion microangiopathy (chronic venous insufficiency and diabetic microangiopathy). J Cardiovasc Pharmacol Ther 7(suppl I): S3-S5, 2002.
9. Belcaro G, Nicolaides AN, Stansby G (eds): The Venous Clinic. London: Imperial College Press, 1999.
10. Belcaro G, Nicolaides AN (eds): Noninvasive Investigations in Vascular Disease. London: Imperial College Press, 2001.
11. 2 measurements in association with laser Doppler flowmetry in venous hypertension. Phlebology 3:189-193, 1988.
12. Belcaro G, Grigg M, Rulo A, et al: Blood flow in the perimalleolar skin in relation to posture in patients with venous hypertension. Ann Vasc Surg 1:5-8, 1989a.
13. Belcaro G, Christopoulos D, Nicolaides AN: Skin flow and swelling in postphlebitic limbs. Vasa 18:136-138, 1989b.
14. Belcaro G, Nicolaides AN, Volteas N, et al: Skin flow, the venoarteriolar response and capillary filtration in diabetics. A three-year follow-up study. Angiology 43:490-494, 1992a.
15. Belcaro G, Bollinger A, Hoffman U, et al (eds): Laser Doppler Flowmetry. London: Med-Orion, 1994.
16. Bollinger A, Jager K, Geser A, et al: Transcapillary and interstitial diffusion of Na-Fluorescein in chronic venous insufficiency with white atrophy. Int J Microcirc I:5-8, 1982b.
17. Fagrell B: Microcirculatory disturbances - the final cause for venous leg ulcers? Vasa 11:101-103, 1982.
18. Fagrell B: Problems using laser Doppler flowmetry on the skin in clinical practice. In: Belcaro G, Hoffman U, Nicolaides AN, et al (eds): Laser Doppler. London: Med Orion, 1994, pp 49-53.
19. Franzeck U, Bollinger A, Huch R, et al: Transcutaneous oxygen tension and capillary morphologic characteristics and density in patients with chronic venous incompetence. Circulation 70:806-809, 1984.
20. Hendriksen O: Local reflex in microcirculation in human subcutaneous tissue. Acta Physiol Scand 97:446-449, 1976.
21. Rayman G, Hassan A, Tooke JE: Blood flow in the skin of the foot related to posture in patients with diabetes mellitus. BMJ 292:87-91, 1986.
22. Thulesius O: Capillary filtration under normal and pathological conditions. Angiologia 10:198-201, 1973.
23. Bergan JJ, Schmid-Schonbein GW, Takase S: Therapeutic approach to chronic venous insufficiency and its complications: Place of Daflon 500 mg. Angiology 52(suppl 1):S43-S45, 2001.
24. Danielsson G, Jungbeck C, Peterson K, et al: A randomized controlled trial of micronized purified flavonoid fraction vs placebo in patients with chronic venous disease. Eur J Vasc Endovasc Surg 23:73-79, 2002.
25. Belcaro G, Cesarone MR, Bavera P, et al: HR (Venoruton 1000, Paroven, 0-[beta-hydroxyethyl]-rutosides) vs Daflon 500 in chronic venous disease and microangiopathy: An independent prospective, controlled, randomized trial. J Cardiovasc Pharmacol Ther 7:139-145, 2002.
26. Cesarone MR, Belcaro G, Pellegrini L, et al: HR, 0-(beta-hydroxyethyl)- rutosides, in comparison with diosmin + hesperidin in chronic venous insufficiency and venous microangiopathy: An independent, prospective, comparative registry study. Angiology 56:1-8, 2005.
27. Belcaro G, Cesarone MR, Ippolito E, et al: Evaluation of quality of life (Ve-QOL) in chronic venous insufficiency and venous disease. AKOM Web J 2:12-15, 2005.
28. Cesarone MR, Belcaro G, Incandela L, et al: Flight microangiopathy in medium-to-long-distance flights: Prevention of edema and microcirculation alterations with HR (Paroven, Venoruton; 0(beta-hydroxyethyl)-rutosides). J Cardiovasc Pharmacol Ther 7(suppl I):S17-S19, 2002.
29. Cesarone MR, Incandela L, De Sanctis MT, et al: Variations in plasma free-radicals in patients with venous hypertension with HR (Paroven, Venoruton; 0(beta-hydroxyethyl)-rutosides): A clinical, prospective, placebo-controlled, randomized trial. J Cardiovasc Pharmacol Ther 7(suppl 1):S25-S28, 2002.
30. Ekestrom S, Welti R: The affinity of hydroxyethyl-rutosides for the venous wall and its efficacy in preventing early occlusion of aorto-coronary vein bypass grafts. Phlebology 5(suppl 1):41-48, 1990.
31. Beckers C, Zijilstra JA: New aspects of the pathogenesis of CVI and the site of action of Venoruton. Phlebology Digest 14:8-11, 2001.
32. Nees S, Juchem G, Fink R: Influence of polymorphonuclear leukocytes and platelets on the barrier function of cultured venular endothelial cells. Proceedings of the 6th World Congress for Microcirculation. Bologna: Monduzzi, 1996, pp 401-404.
33. Roland IH, Bougelet C, Ninane N, et al: Effect of hydroxyethylrutosides on hypoxial-induced neutrophil adherence to umbilical vein endothelium. Cardiovasc Drugs Ther 12:375-381, 1998.